What is Vycor Medical Financial Strength?
Vycor Medical has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Vycor Medical did not have earnings to cover the interest expense.
Vycor Medical's debt to revenue ratio for the quarter that ended in Sep. 2024 was 0.69.
As of today, Vycor Medical's Altman Z-Score is -46.26.
Competitive Comparison of Vycor Medical's Financial Strength
For the Medical Devices subindustry, Vycor Medical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vycor Medical's Financial Strength Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's Financial Strength distribution charts can be found below:
* The bar in red indicates where Vycor Medical's Financial Strength falls into.
Vycor Medical Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Vycor Medical's Interest Expense for the
months ended in Sep. 2024 was $-0.03 Mil. Its Operating Income for the
months ended in Sep. 2024 was $-0.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.21 Mil.
Vycor Medical's Interest Coverage for the quarter that ended in Sep. 2024 is
| Vycor Medical did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Vycor Medical's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Vycor Medical has a Z-score of -46.26, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -46.26 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vycor Medical Business Description
Traded in Other Exchanges
N/A
Address
951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487
Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.
Executives
| David Cantor |
director, officer: President |
1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000 |
| Adrian Liddell |
director, officer: Chairman |
ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP |
| Peter C Zachariou |
director, 10 percent owner, officer: Chief Executive Officer |
C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014 |
| Lowell Rush |
director |
C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394 |
| Oscar Bronsther |
director |
4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380 |
| Steven Girgenti |
director |
C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013 |
| Fountainhead Capital Management Ltd |
10 percent owner |
PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VYCO has been successfully added to your